Muscle Function Following Anterior Cruciate Ligament Reconstruction: Impaired Power Output in Physically Active Individuals (ReGAIN)

August 10, 2026 updated by: Centre Hospitalier Metropole Savoie

The goal of this clinical trial is to to determine the extent of the association between objective changes in the muscle function of the knee extensors (strength and power) and the function reported by the patient following ACL reconstruction surgery. The main questions it aims to answer is:

- Pre- and post-operative (6 months) changes in maximum knee extensor strength following ACL reconstruction, correlated with the IKDC-SKF score.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Before surgery :

  • The patient will undergo a series of assessment tests, including:
  • An assessment of the force-velocity and power-velocity relationships for each leg during a cycling task
  • An assessment of unilateral force-velocity and power-velocity relationships during a knee extension task
  • An assessment of maximum strength and explosive strength in isometric (static) mode of the knee extensors.
  • A questionnaire-based assessment of IKDC-SKF scores. Evaluations will be repeated at 3 and 6 month after surgery ; Patients will be monitored for up to 24 months following their surgery

Study Type

Interventional

Enrollment (Estimated)

110

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients requiring isolated or complex ACL reconstruction (combined with a meniscal injury)
  • Patients who are physically active (Tegner score ≥ 4) and wish to resume such activity.
  • Patients with no history of surgery on the ipsilateral knee (i.e., native knee).
  • Patients able to comply with the study procedures
  • Patients who have given their free and informed written consent, having been informed of the purpose of the study, its procedure and its risks.
  • Be affiliated to a social security scheme.

Exclusion Criteria:

  • Patient with comprehension difficulties
  • Recurrent rupture of the ipsilateral ACL
  • Multi-ligament injuries (i.e., injury to the medial collateral ligament, lateral collateral ligament or posterior cruciate ligament)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: evaluated group
assessment of knee function before and after cruciate ligament surgery
  • Assessment of force-velocity and power-velocity relationships in each leg during a cycling task
  • Assessment of unilateral force-velocity and power-velocity relationships during a knee extension task
  • Assessment of maximum force and explosive force in isometric (static) conditions of the knee extensors.
  • Measurement of scores using questionnaires (IKDC-SKF).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlation of maximum knee extension strength to IKDC-SKF scores
Time Frame: 6 month
Relationship (r coefficient) between 0-6 month delta of maximum knee extension strength measurements and International Knee Documentation Commitee-SKF scores (100: no limitation)
6 month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Peri-operatory trajectory of maximal dynamic force
Time Frame: 0, 3 and 6 month
Trajectory of evolution of F0 (maximal dynamic force) between baseline, 3 and 6 months, compared between legs (linear mixed effect model).
0, 3 and 6 month
Peri-operatory trajectory of maximal contraction velocity
Time Frame: 0, 3 and 6 month
Trajectory of evolution of V0 (maximal contraction velocity) between baseline, 3 and 6 months, compared between legs (linear mixed effect model).
0, 3 and 6 month
Peri-operatory trajectory of rate of force development
Time Frame: 0, 3 and 6 month
Trajectory of evolution of rate of force development between baseline, 3 and 6 months, compared between legs (linear mixed effect model).
0, 3 and 6 month
Peri-operatory trajectory of maximal isometric force
Time Frame: 0, 3 and 6 month
Trajectory of evolution of maximal isometric force (Fmax) between baseline, 3 and 6 months, compared between legs (linear mixed effect model).
0, 3 and 6 month
Peri-operatory trajectory of maximal dynamic force during cycling
Time Frame: 0, 3 and 6 month
Trajectory of evolution of maximal dynamic force (F0) during cycling between baseline, 3 and 6 months (linear mixed effect model, one fixed factor).
0, 3 and 6 month
Peri-operatory trajectory of maximal contraction velocity during cycling
Time Frame: 0, 3 and 6 month
Trajectory of evolution of maximal contraction velocity (V0) during cycling between baseline, 3 and 6 months (linear mixed effect model, one fixed factor).
0, 3 and 6 month
Determinants of fonctional prognosis
Time Frame: 0, 3 and 24 month

Multivariate analysis including the IKDC-SKF score at 24 months as dependant variable and, as predictors :

  1. the 0-3 month delta of V0, F0, RFD and Fmax during knee extension on the operated leg.
  2. the severity of the lesion (presence of associated lesions)
  3. the presence of a pre-operatory rehabilitation.
0, 3 and 24 month
Determinants of fonctional prognosis
Time Frame: 0, 3 and 24 month

Multivariate analysis including the recurrence of ACL lesion at 24 months (0/1) as dependant variable and, as predictors :

  1. the 0-3 month delta of V0, F0, RFD and Fmax during knee extension on the operated leg.
  2. the severity of the lesion (presence of associated lesions)
  3. the presence of a pre-operatory rehabilitation.
0, 3 and 24 month
Determinants of fonctional prognosis
Time Frame: 0, 3 and 24 month

Multivariate analysis including resuming physical activity at the pre-injury level at 24 months (0/1) as dependant variable and, as predictors :

  1. the 0-3 month delta of V0, F0, RFD and Fmax during knee extension on the operated leg.
  2. the severity of the lesion (presence of associated lesions)
  3. the presence of a pre-operatory rehabilitation.
0, 3 and 24 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 8, 2026

Primary Completion (Estimated)

June 8, 2030

Study Completion (Estimated)

June 8, 2030

Study Registration Dates

First Submitted

June 1, 2026

First Submitted That Met QC Criteria

August 10, 2026

First Posted (Actual)

August 14, 2026

Study Record Updates

Last Update Posted (Actual)

August 14, 2026

Last Update Submitted That Met QC Criteria

August 10, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe